BioMarin's Biggest Rival Just Got Benched for Three Extra Months

The clinical data is compelling too. In the Phase 3 ApproaCH trial, 84 children aged 2 to 11 received either TransCon CNP or placebo. Kids on the drug grew at 5.89 cm per year, compared to 4.41 cm per year on placebo. That's a statistically significant difference of 1.49 cm per year. The effect was even more pronounced in older kids aged 5 to 11, where the treatment difference hit 1.78 cm per year.

Beyond just growing taller, the trial showed improvements in lower limb alignment, spinal canal dimensions, and muscle strength. TransCon CNP works as a long-acting version of C-type natriuretic peptide, essentially a sustained-release formulation that keeps working between doses instead of spiking and fading every day.

On paper, this is a real competitor. On a calendar, it's still stuck in the waiting room.

Why Three Months Is an Eternity in Rare Disease

Rare disease markets don't work like selling cholesterol drugs to millions of people. The patient populations are small. The prescribing physicians are a tight-knit group of specialists. And once a doctor gets comfortable with a drug, once they've figured out the dosing, navigated insurance approvals, and seen results in their patients, switching is a pain.

Every month that Voxzogo operates without competition, BioMarin's sales team is knocking on doors, locking in reimbursement deals, and building relationships with the endocrinologists and geneticists who treat achondroplasia. It's the same reason first apps on your phone are so hard to delete. You've already invested time learning the interface.

BioMarin also isn't standing still on the science. The company expects to share Phase 3 data for Voxzogo in hypochondroplasia, a related skeletal condition, in 2026, with a potential launch in 2027. Analysts have projected peak sales exceeding $5 billion across different indications. That's a company actively expanding its territory while its rival waits for a permission slip.

The Delay Isn't a Death Sentence

Let's be clear about what this PDUFA delay is and isn't. It's not the FDA saying no. It's not a safety concern. Ascendis CEO Jan Mikkelsen emphasized continued collaboration with the agency, and the company says it has responded to all outstanding FDA requests.

Major amendment extensions are standard procedure under PDUFA VII, the latest reauthorization of the law that governs FDA review timelines. When a company submits significant new information during the review cycle, the FDA can tack on three months. It happens. The FDA hit its review targets on 97% of applications in 2023, so the machinery generally works on schedule.

But "standard procedure" doesn't mean "no consequences." Three months of delay means three months of investor uncertainty for Ascendis. It means three months where doctors who might have waited for a weekly option decide to start patients on Voxzogo instead. In pediatric medicine, once a child is responding well to a treatment, the bar for switching gets very high. No parent wants to mess with what's working.

The Bigger Picture

The achondroplasia market is getting more interesting, not less. Beyond TransCon CNP, Tyra Biosciences is developing an oral drug called dabogratinib that could eventually challenge both injectable options. Phase 2 trials started in August 2024, so it's still early, but the idea of a pill replacing weekly or daily shots is the kind of thing that keeps both BioMarin and Ascendis up at night.

For now, though, this is a two-horse race where one horse is already running and the other is still in the starting gate. Ascendis has a drug that could genuinely change the treatment experience for thousands of families. But the clock, and the competition, aren't waiting.

BioMarin didn't ask for this three-month gift. But you can bet they're going to use every single day of it.

Moderna Just Sold a Rare Disease Drug for Pennies on the Dollar

Moderna handed Recordati the commercial rights to a potentially first-in-class rare disease therapy for just $50 million upfront. Leerink analysts called it a "garage sale," and the math backs them up.